Bridgebio Pharma, Inc. BBIO Stock Forecast
AI-powered price prediction and analysis for Bridgebio Pharma, Inc. · Alpha · vs marketSwitch to Total
See BBIO's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Bridgebio Pharma, Inc.
Bridgebio Pharma, Inc. (BBIO) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
Where BBIO sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| BBIO Bridgebio Pharma, Inc. | $14.42B | – | |
| LLY Eli Lilly & Co | $1.33T | 45.7x | |
| JNJ Johnson & Johnson | $640.75B | 40.5x | |
| ABBV Abbvie Inc. | $521.11B | 76.2x | |
| MRK Merck & Co., Inc. | $356.93B | 115.7x | |
| NVS Novartis Ag | $303.89B | 9.6x | |
| AZN Astrazeneca Plc | $285.01B | 13.3x | |
| ABT Abbott Laboratories | $190.23B | 30.6x | |
| NVO Novo Nordisk A S | $177.76B | 3.0x | |
| PFE Pfizer Inc | $170.99B | 38.0x | |
| VRTX Vertex Pharmaceuticals Inc / … | $136.87B | 31.5x | |
| BMY Bristol Myers Squibb Co | $126.14B | 13.7x | |
| SNY Sanofi | $106.33B | – | |
| REGN Regeneron Pharmaceuticals, Inc. | $100.21B | 21.6x | |
| GSK Gsk Plc | $98.25B | 5.4x | |
| TAK Takeda Pharmaceutical Co Ltd | $62.51B | 6.0x | |
| TEVA Teva Pharmaceutical Industries Ltd | $48.84B | 40.3x | |
| ONC Beone Medicines Ltd. | $40.36B | 1224.2x | |
| GMAB Genmab A/S | $36.34B | 2.3x | |
| ZTS Zoetis Inc. | $34.29B | 13.7x | |
| RPRX Royalty Pharma Plc | $28.77B | 38.4x | |
| ROIV Roivant Sciences Ltd. | $26.03B | – | |
| UTHR United Therapeutics Corp | $25.79B | 21.6x | |
| INSM Insmed Inc | $22.91B | – | |
| VTRS Viatris Inc | $21.73B | – | |
| ALNY Alnylam Pharmaceuticals, Inc. | $21.42B | 7.5x | |
| ASND Ascendis Pharma A/S | $16.43B | – | |
| JAZZ Jazz Pharmaceuticals Plc | $14.91B | 75.8x | |
| SMMT Summit Therapeutics Inc. | $12.60B | – | |
| ELAN Elanco Animal Health Inc | $12.28B | – | |
| RDY Dr Reddys Laboratories Ltd | $11.83B | 15.6x | |
| BMRN Biomarin Pharmaceutical Inc | $10.77B | 556.6x | |
| TGTX Tg Therapeutics, Inc. | $9.22B | 21.9x | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.16B | – | |
| PTGX Protagonist Therapeutics, Inc | $9.07B | 177.5x | |
| CORT Corcept Therapeutics Inc | $8.86B | 49.1x | |
| SYRE Spyre Therapeutics, Inc. | $8.75B | – | |
| CYTK Cytokinetics Inc | $8.66B | – | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.54B | – | |
| PRAX Praxis Precision Medicines, Inc. | $7.83B | – | |
| ALKS Alkermes Plc. | $7.67B | 44.4x | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.33B | 86.4x | |
| AXSM Axsome Therapeutics, Inc. | $7.31B | – | |
| IONS Ionis Pharmaceuticals Inc | $7.23B | – | |
| ABVX Abivax S.A. | $6.97B | – | |
| ORKA Oruka Therapeutics, Inc. | $6.59B | – | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.45B | 61.2x | |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.37B | – | |
| LGND Ligand Pharmaceuticals Inc | $6.27B | 119.7x | |
| BLTE Belite Bio, Inc | $5.99B | – | |
| PTCT Ptc Therapeutics, Inc. | $5.69B | – | |
| MIRM Mirum Pharmaceuticals, Inc. | $5.61B | – | |
| MANE Veradermics, Inc | $5.58B | – | |
| COGT Cogent Biosciences, Inc. | $5.39B | – | |
| ERAS Erasca, Inc. | $5.12B | – | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.63B | – | |
| TVTX Travere Therapeutics, Inc. | $4.42B | – | |
| INDV Indivior Pharmaceuticals, Inc. | $4.17B | 8.6x | |
| EWTX Edgewise Therapeutics, Inc. | $4.09B | – | |
| LQDA Liquidia Corp | $4.03B | 104.8x |
FAQ
Is Bridgebio Pharma, Inc. a good stock to buy?
Our AI analyzes Bridgebio Pharma, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Bridgebio Pharma, Inc. predictions?
For BBIO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 7.0%, measured on 358 forecast dates between 2022-08-17 and 2026-08-06 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 11.0%, measured on 400 forecast dates between 2022-08-17 and 2026-10-05. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Bridgebio Pharma, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 4, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Bridgebio Pharma, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.